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ABSTRACT: Serum free light chain (sFLC) assays are well established in the
diagnosis and monitoring of plasma cell disorders. However, current FLC
immunoassays are subject to several analytical issues, which results in a lack of
harmonized results. To facilitate sFLC standardization, we investigated the
strengths and limitations of mass spectrometry as a novel technological platform
for sFLC quantiﬁcation. Stable isotope labeled reference peptides are added to
serum samples for quantitation by selected reaction monitoring (SRM). The use
of redundant peptide sets allows for quality control measures during data
analysis. Measurements on serum provide information on intact immunoglo-
bulins, but depletion of these intact molecules from the sera during sample
processing permits the quantitation of sFLC. sFLC concentrations measured with SRM were comparable to those obtained by
nephelometry and showed excellent linearity (r2 > 0.99). In samples with high levels of sFLC, SRM data was more consistent
with serum protein electrophoresis than nephelometric data and SRM is unaﬀected by antigen excess. The lower limits of
quantitation were 3.8 and 2.7 mg/L for κ and λ sFLC. Errors due to polymorphic sequences were prevented by comparison of
redundant peptide pairs. The application of stable isotope labeling combined with SRM can overcome many of the current
potential analytical issues of sFLC analysis. We describe which hurdles still need to be taken to make SRM a robust and more
accurate method for sFLC measurements.
Monoclonal gammopathies are characterized by the clonalexpansion of plasma cells in the bone marrow and by the
production of monoclonal immunoglobulins (M-proteins).
These disorders range from benign, monoclonal gammopathy
of undetermined signiﬁcance, to symptomatic myeloma with
bone destruction, bone marrow suppression, and renal damage.
The International Myeloma Working Group has established
criteria for the diagnosis of these plasma cell dyscrasias.1,2 The
detection and quantiﬁcation of M-proteins involves serum and
urine electrophoresis and immunoﬁxation, nephelometric
analysis of serum immunoglobulins and of serum free light
chain (sFLC). The quantiﬁcation of M-proteins and mono-
clonal sFLC is technically challenging, which is among others
demonstrated by considerable intermethod diﬀerences.3−8
Accurate and sensitive quantiﬁcation is essential for the
monitoring of monoclonal gammopathies.9 Here, we present
a quantitative LC−MS procedure that allows us to characterize
both intact immunoglobulins and their free light chains in
serum.
Free Light Chains. Plasma cells synthesize approximately
40% excess of light chains to allow eﬃcient assembly of the
immunoglobulin heavy and light chain heterodimer. The excess
of light chains is excreted into the circulation as sFLC and
ﬁnally cleared renally.10 In patients with impaired renal
clearance, sFLC may also be elevated in absence of a plasma
cell dyscrasia, albeit not in a monoclonal fashion. The clonal
character is reﬂected in the ratio between the κ and λ chains of
the sFLC.11
Existing Tests. Measurement of sFLC has become well
established in the diagnosis and follow-up of monoclonal
gammopathies improving the screening, the risk-assessment,
and the evaluation of response to therapy.9,12,13 sFLC analysis
in the clinics is dominated by nephelometric and turbidometric
immunoassays.11,12 However, quantiﬁcation of sFLC by these
methods is subject to diﬃculties such as inconsistency in linear
responses, imprecision caused by lot-to-lot variation and
interanalyzer variation, poor accuracy, and antigen-ex-
cess.4−6,14−18 Recently a second commercial FLC assay was
introduced which is based on monoclonal detection reagents.19
Because of signiﬁcant diﬀerences in sFLC concentrations
between nephelometric tests from both vendors, they cannot
be used interchangeably in individual patients.19−22 Measure-
ment of sFLC and its standardization is diﬃcult because each
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individual patient has a unique monoclonal FLC, with
considerable heterogeneity in size, charge, isoelectric point,
and concentration of FLCs.4,23 Lack of harmonization is further
magniﬁed by the diversity of polyclonal and monoclonal-based
immunochemical FLC-methods. An internationally accepted
FLC reference-method or -material is currently not available.
Since diagnosis, prognosis, and monitoring of patients rely on
accurate sFLC measurements, standardization is urgently
needed.
The LC−MS method described in this paper quantiﬁes sFLC
in a fundamentally diﬀerent manner than nephelometric
immunoassays, as it relies on the measurement of the
concentration of proteolytic peptides from the analyte, rather
than an aﬃnity interaction of a nephelometry reagent with an
epitope on the analyte. Thus, our method may not share the
problems of nephelometry described above. The role for mass
spectrometry in immunoglobulin quantiﬁcation was recently
expanded by several groups who describe an LC−MS method
to quantify IgG subclasses using SRM.24−27 While similar to the
current method with regard to intact immunoglobulins, our
capability to quantify sFLC is an important addition. Moreover,
the method in this paper relies on an extended set of peptides,
which increases robustness and the possibilities for quality
control.
■ EXPERIMENTAL SECTION
Chemicals were obtained from Sigma-Aldrich (St. Louis, MO)
unless reported otherwise.
Reference Standards. For quantiﬁcation, stable isotope
labeled peptides were obtained as internal standards for
peptides for the immunoglobulin chains of interest (Pepscan
BV, Lelystad, The Netherlands).28 Peptide amount and purity
were established by amino acid analysis, HPLC, and MS by the
manufacturer. In addition, some peptides were analyzed by
quantitative NMR (qNMR) using a 500 MHz instrument
(Bruker, The Woodlands, TX), maleic acid as qNMR reference,
trimethylsilyl propanoic acid as chemical shift reference, and
D2O as a lock signal.
Certiﬁed Reference Material (CRM) ERM-DA470k/IFCC
was included as a serum protein reference (Institute for
Reference Materials and Measurements, Belgium).29 The
sensitivity of the SRM method was assessed by titrating
puriﬁed human κ and λ free light chains (Bethyl Laboratories,
Montgomery, TX) in a serum matrix from an aplastic phase
following stem cell transplantation, low in endogenous
immunoglobulins.
Patient Cohort. Sera were derived from routine diagnostic
samples of which sFLC analysis was requested at the
Department of Laboratory Medicine at the Radboudumc,
Nijmegen, The Netherlands. Aliquots were archived at −80 °C
after collection and thawed directly before further analysis. Sera
were retrospectively selected to obtain a cohort of samples with
a wide range of both κFLC and λFLC, with or without the
presence of intact monoclonal immunoglobulins. Sera were
derived from healthy controls, patients with chronic kidney
disease, and patients with a variety of monoclonal gammo-
pathies. All samples and clinical data were coded and
anonymized as speciﬁed in the Dutch code of conduct for
biomedical research.
Conventional M Protein Analysis. For M-protein
quantiﬁcation and characterization, agarose gel electrophoresis
and immunoﬁxation electrophoresis were performed on the
Hydrasys (Sebia, Evry, France) using reagents from Sebia
according to the manufacturer’s protocol. Nephelometric serum
IgG, IgA, and IgM were measured on an Immage 800 analyzer
(Beckman Coulter, Fullerton, CA) according to the manu-
facturers’ protocol. Both Freelite FLC (The Binding Site,
Birmingham, U.K.) and N Latex FLC (Siemens, Marburg,
Germany) assays were performed on a BNII analyzer according
to the manufacturer’s protocols. The reference ranges for both
assays were as published previously.19,30
Sample Preparation. Sera were cleared for 5 min at
20 000g in a centrifuge and, as serum volumes were limited, a
small 4 μL aliquot was taken. The serum was diluted in 1200
μL of PBS containing reference peptides at 16.6 nM each. For
the quantitation of intact immunoglobulins, this material was
used directly for reduction, alkylation, and digestion; for the
quantitation of sFLC, intact immunoglobulins were ﬁrst
depleted from the sample.
To deplete intact immunoglobulin G, agarose beads coupled
to protein A and G (Thermo Fisher Scientiﬁc, MA) were used.
To also deplete IgA, goat antihuman IgA (Jackson Immunor-
esearch Europe, U.K.) was included, immobilized on the
protein A/G beads before addition of serum samples.
Additional depleting antibodies could be included in a similar
manner if required. We prepared and measured samples in
duplicate for the depleted samples and included one sample
with undepleted serum for each patient. The diluted sera were
incubated for 1 h with the Protein A/G beads (15 μL packed
beads/75 μL diluted serum), after which a ﬁltrate was collected.
A volume of 30 μL was diluted in 30 μL of 50 mM ammonium
bicarbonate, 10 mM DTT, 0.2% Rapigest SF (Waters, MA).
After reduction at 60 °C for 30 min, cysteine residues were
alkylated with 15 mM iodoacetamide (15 min, 25 °C). Finally,
30 mM DTT and 600 ng of trypsin (Promega, WI) were added,
quenching the alkylation and digesting overnight at 37 °C.
Triﬂuoroacetic acid was added to 0.5%, after centrifugation (5
min 20 000g) samples were injected on the LC−MS. The
procedure has been summarized in Figure 1.
LC−MS. Chromatography was performed on a nano-LC
(Dionex Ultimate 3000, ThermoFisher Scientiﬁc, MA).
Samples were separated on a C18 column (Dionex Acclaim
PepMap100, 3 μm, 100 Å, 75 μm i.d. × 15 cm) using a gradient
of 0.1% formic acid to 80% acetonitrile with 0.1% formic acid.
Mass spectrometry was performed on a Qtrap 4000 mass
spectrometer (AB Sciex, MA) with a nanospray source. Table
S-1 in the Supporting Information shows all SRM peptides and
the associated masses used in the method, typically three
transitions per peptide. We used a scheduled SRM method with
a 200 s measurement window around the predicted retention
time, as deﬁned with a test run of the peptide standards and the
iRT algorithm in the Skyline software package. The Analyst
mass spectrometer software determines the dwell times based
on a 3 s cycle time. Additional measurements were performed
on a Xevo TQ-S (Waters, MA) to compare portability and
sensitivity or on a LTQ Orbitrap XL (Thermo Fisher Scientiﬁc,
MA) to identify polymorphisms.
Data Processing. Signals were integrated using Skyline and
exported for further analysis.31 The concentration of each
peptide was determined based on the signal ratio between the
endogenous peptide and the spiked internal standard peptide.
Subsequently, peptide concentrations were aggregated to the
protein level by summing sequence variants and averaging
peptides belonging to the same protein chain. This process has
been illustrated by equations in Figure S-1 in the Supporting
Information. No corrections were applied for intact immuno-
Analytical Chemistry Article
DOI: 10.1021/acs.analchem.5b01263
Anal. Chem. 2015, 87, 8268−8274
8269
globulins remaining after depletion, as the relative contribution
of κ and λ light chains cannot be determined. De novo
sequencing of orbitrap data was performed using Peaks Studio
6 (Bioinformatics Solutions, ON, Canada).
Quality Control. Several transitions are included to
monitor potential chemical modiﬁcations and integrity of the
selected peptides. As peptides with cysteine or methionine had
to be included, controls for potential artifacts were measured.
The oxidation of methionines is monitored by measuring an
oxidized peptide, the degree of alkylation of cysteines by
measuring an unalkylated peptide, and the degree of digestion
by measuring several peptides containing a missed cleavage. A
list of these peptides for quality control is incorporated in Table
S-1 in the Supporting Information, labeled as “QC” in the
protein column. The results from these QC measurements was
monitored for outliers or unusual patterns. Furthermore, the
reliability of the data is assessed by comparing results for
peptides belonging to the same protein. Inconsistencies
between such cognate sets indicate analytical artifacts or
sequence polymorphisms. Within a peptide, the ratio of the
contributing fragment ions should remain similar between
samples. The success of the depletion of intact immunoglobu-
lins has been assessed through peptides from the heavy chain.
Safety Considerations. Serum samples are a biohazardous
material and should be treated as such.
■ RESULTS AND DISCUSSION
Serum Depletion. Immunoglobulin light chains exist in
serum unbound as part of intact immunoglobulins or as free
light chains. After proteins are digested with a protease, it is no
longer possible to distinguish light chain peptides derived from
intact immunoglobulins from those that existed as free light
chains. As sFLC are typically present in a much lower
concentration than total immunoglobulins (10 mg/L sFLC vs
10 g/L intact immunoglobulins for healthy individuals), the
contribution of free light chains cannot be determined reliably
from the stoichiometry between heavy and light chains. Also, it
is important to measure the ratio between κ and λ sFLC, while
results would reﬂect a ratio from sFLC and intact
immunoglobulins combined. It is therefore necessary to deplete
the intact immunoglobulins from the sample. Undepleted
samples were still measured, as they remain valuable to help the
interpretation of sFLC data and for additional diagnostic
capabilities for abnormalities in intact immunoglobulins and
rare heavy chain gammopathies.24,32 The depletion was
eﬀective for both IgG and IgA, leaving on average 0.75% of
the initial amount for IgG (Figure S-2 in the Supporting
Information). The amount of IgG remaining after depletion still
results in a detectable signal of associated light chains which,
while mostly below the level of (free) light chains in healthy
subjects, is not desirable and may be improved upon.
Sensitivity, Linearity, and Variation. The sensitivity of
the assay is determined by the combination of measurements
made for the peptides in the SRM set. The result of several
peptides is averaged in the result of a protein chain, and such
aggregated data was used to assess the lower limit of
quantitation (LLoQ) of the assay.
We tested the sensitivity by spiking puriﬁed κ and λ light
chains in a serum matrix low in endogenous immunoglobulins.
The LLoQ was deﬁned as 10 × SDblank/slope and was 3.8 mg/L
for κ and 2.7 mg/L for λ chains. As can be seen from Figure 2,
the results were linear over 3 logs (rλ
2 = 0.996; rκ
2 = 0.993)
until signals were lost. For the best performing peptides, a small
signal could be observed in the aplastic serum alone, suggesting
endogenous sFLC levels in this matrix on the order of 1 mg/L
for both κ and λ chains. Reanalysis of the samples on a diﬀerent
mass spectrometer (Xevo TQ-S, Waters, MA, data not shown)
resulted in data with a LLoQ of 0.7 mg/L for κ and 0.9 mg/L
for λ and indicated an endogenous sFLC level of 2 mg/L in the
aplastic serum.
On the basis of the samples spiked with more than the
LLoQ, the average CV was 6.6% for κ and 2.9% for λ. However,
CVs were higher for the replicates that were measured in the
cohort, on average 19.7% and 13.6% for κ and λ, respectively.
This may be related to the low median sFLC concentration in
the cohort (15 and 34 mg/L), to variations associated with the
handling of a larger number of samples or to the longer time
Figure 1. Flowchart of the sample preparation used to quantify
immunoglobulins and sFLC using selected reaction monitoring.
Figure 2. LLoQ of the sFLC assay. Puriﬁed sFLC of both κ and λ type
were titrated in a matrix of an aplastic serum sample and the
concentration of sFLC was determined by SRM. The linear curve ﬁt is
based on spiked concentrations of sFLC of 4 mg/L and higher.
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lapsed between injection of the replicated on the LC−MS
system.
Cross-Checks and Quality Controls. Results from most
peptides can be compared to their cognate counterparts from
the same protein chain for consistency. We compared several
such peptide sets, as illustrated in Figure 3. For a given protein
concentration, the same concentration is expected for both
peptides derived from it. While most peptides showed a good
correlation with each other, some data points deviate from the
general distribution. This may indicate sequence polymor-
phisms in that patient, as discussed in the following section. In
addition, the measurements do not align perfectly to the
diagonal that represents identical outcomes, indicating that
some inaccuracies remain in the calibration of some peptides.
Where possible, an additional characterization was performed
on the peptide standards by qNMR. Most measurements
agreed with the manufacturer’s data, but deviations up to 40%
were also observed. The manufacturer’s data was used as the
basis for all quantitation, and the qNMR results were included
in Table S-1 in the Supporting Information.
Signals from the oxidized form of the peptide DTLMISR
amounted to 1−2% of that of the normal form and were stable
over time (Figure S-3A in the Supporting Information). We do
not have calibrated data for the oxidized form, but assuming
that the detector response is similar for both peptides, the ratio
found was deemed acceptable. Moreover, the ratio did not
change much during the measurement period (22 days), and
any oxidation events would equally aﬀect endogenous and
standard peptides. Thus, methionine oxidation was not a
problem in this data set. From the same measurements, we did
see a gradual decrease in signal from both the endogenous
peptide and the standard peptide. This suggests that the
peptide is slowly lost from the sample by another mechanism,
for example, adsorption to the vial wall. Again, this is corrected
for by the internal standard, but nevertheless it is recommended
to measure samples within days or at most weeks after
preparation is complete. We also compared a tryptic peptide
with an extended peptide with a missed cleavage. The
miscleaved peptide signal was correlated (R2 0.91) to the
tryptic peptide, suggesting that a constant fraction of the
protein evades digestion (Figure S-3B in the Supporting
Information). As the relative amount of these unwanted forms
of the peptides was low we conclude that neither these artifacts,
nor the missed alkylation of cysteines residues (Figure S-3C in
the Supporting Information), had a signiﬁcant adverse eﬀect on
the data.
Polymorphisms. Peptides were chosen to cover the
sequence variants found in humans as reported in the IMGT
database.33 However, rare or novel sequence variants may still
occur, and the occurrence of a polymorphic peptide will aﬀect
the quantitation in the SRM assay. In order to account for
polymorphisms, two or more peptides per protein chain are
quantiﬁed, which will reveal a polymorphism as a discrepancy in
the data. To further characterize polymorphisms, we analyzed a
subset of 37 samples on an Orbitrap mass spectrometer in
order to elucidate suspected variants of immunoglobulin
peptides. The data set was analyzed using a protein database
consisting of known SNPs from the hg19 reference genome as
well as by de novo sequencing of the MS/MS data.34,35 The
most frequent polymorphism aﬀecting our data occurred in the
IgA peptide SAVQGPPER to SAVQGPPDR. This variant was
absent in the IMGT database but can be found in databases
such as Kabat.36 Reanalysis of the original LC−MS samples
with transitions for the mutated peptide showed evidence for
the variant peptide in 39% of the samples (34% reported in the
ExAC database). In addition, we found in one serum a possible
polymorphism for IgM, YVTSAPMPEPQAPGR to YVTSAPV-
PEPQAPGR. Finally, the ExAC exome database was screened
for additional polymorphisms in peptides of interest.37
Polymorphisms with a prevalence of more than 1% that were
Figure 3. Correlation of cognate peptide pairs. The concentration of
peptide pairs derived from the same protein chain for sera from the
cohort and pairs from IgA (SAVQGPPER and YLTWASR), IgM
(VTSTLTIK and YVTSAPMPEPQAPGR), and the λ light chain
(YAASSYLSLTPEQWK and SYSCQVTHEGSTVEK) are shown.
Figure 4. Comparison between the SRM test for sFLC and the commercial Freelite assay for κ sFLC (A), λ sFLC (B), and κ/λ ratio (C). Shown are
the results for those samples from the cohort that have data available from both tests in the comparison. Data points in red triangles contain intact
immunoglobulin classes that could not be depleted with the current protocol and add signal to our light chain quantitation. Figure S-4 in the
Supporting Information shows similar comparisons between SRM, Freelite, and N-Latex data. Each plot shows the slope and r2 after linear regression
on log-transformed data (black markers only). The LLoQ of the SRM method is shown by an additional tick on the Y-axis.
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not yet accounted for in the SRM transition set have been
annotated in Table S-1 in the Supporting Information. Peptides
with common polymorphisms, interfering peaks, or other
inconsistencies were removed from the ﬁnal computation
method of sFLC. For incidental polymorphisms, concentrations
can still be determined based on data from only the wild-type
peptide. In our cohort, the polymorphisms that were found did
not aﬀect the light chain and computation of sFLC.
Patient Data. The pairwise comparison of the current SRM
assay with the Freelite assay (Figure 4) and the N-latex assay
(Figure S-4 in the Supporting Information) shows that all tests
give comparable results for most samples. Data from the
healthy controls are included in Figure 4 and Figure S-4 in the
Supporting Information but were also summarized in Table S-2
in the Supporting Information. Only patients with a
gammopathy involving one of the immunoglobulin classes
that was not included in our depletion protocol had deviating
results (aﬀected points highlighted in red, intact immunoglo-
bulins conﬁrmed in depleted and whole serum data). Although
the current method allows the identiﬁcation of these samples as
abnormal, depletion of the additional classes of immunoglobu-
lin is required for proper quantiﬁcation of these samples. This
requires feasible adaptations in the sample preparation
protocol.
We computed the r2 for a linear ﬁt of κ, λ, or κ/λ ratio
between log transformed data derived from the SRM and
nephelometry assays, excluding the samples that could not be
completely depleted. We obtained r2 values ranging between
0.81 and 0.96 and slopes between 0.58 and 0.81, as annotated
in Figure 4 and Figure S-4 in the Supporting Information.
Thus, the diﬀerent methods do produce results that are
correlated which each other. However, the slopes deviate from
1, which indicate that the methods yield data that has an oﬀset
from each other between the methods. The data show that, for
a given sample, results for both κ and λ chains rank as Freelite >
N-Latex > SRM. These diﬀerences complicate the comparison
of data from diﬀerent platforms, as mentioned in the
introduction, and illustrate the need for harmonization. The
cause of the diﬀerences is not known, but it may relate to the
source, type, or other heterogeneities between the calibrants
that are used on the diﬀerent systems.
Serum protein electrophoresis (SPE) is an additional tool for
sFLC quantiﬁcation but due to limits in sensitivity only in
samples with suﬃciently high levels of sFLC. In Table S-3 in
the Supporting Information, we list four such sera from the
cohort, in which can be observed that the SRM data are in
better agreement with the SPE result than either one of the
nephelometric assays. Moreover, the nephelometry platforms
also show considerable disagreement among each other, further
bolstering conﬁdence in the data from SRM and SPE.
As the SRM approach can also be well suited for the
quantitation of intact immunoglobulins, we also processed
whole serum from every patient to quantify intact IgA, IgG,
IgE, and IgM. Only qualitative measurements were included for
IgD as well as subclass speciﬁc peptides for IgG1−4. As shown in
Figure 5, samples with known M-proteins (>10 g/L) are readily
identiﬁed by SRM and IgG M-proteins can be resolved to one
of its subclasses in panel B. For the CRM serum, the data could
be compared to the certiﬁed values accompanying the serum.
As shown in Table S-4 in the Supporting Information, we
found good agreement for IgA and IgM and a somewhat lower
value for IgG.
Data Analysis. The richness of the data is a strength of the
SRM approach but could also be perceived as a liability. Users
should not routinely be exposed to the complexities of the
underlying data set. It would be desirable to automate data
analysis and quality control procedures and report a ﬁnal result
at the desired level of detail. This report could be associated
with a quality metric to conﬁrm that all cross-checks remained
within bounds, with no suspicion of polymorphisms or other
irregularities. In the current paper, data analysis was mostly
performed manually in a spreadsheet and a robust platform for
Figure 5. Data from undepleted sera for intact immunoglobulins. Abundances for (A) the main immunoglobulin classes IgG, IgA, IgM, IgE, and IgD.
Samples that were known to contain M-proteins in excess of 10 g/L from available clinical data are highlighted with a marker matching for the class
in the top of the ﬁgure. Data for IgD is plotted with uncalibrated intensity data on the right Y-axis. The other panel (B) shows data for subclasses
IgG1, IgG2, IgG3, and IgG4. All data are uncalibrated intensity data, and those for IgG4 are on the right Y-axis.
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an automated approach remains to be established. Moreover,
tolerance limits on all quality metrics remain to be thoroughly
established based on routine operation of the assay.
Accuracy. The oﬀset between results from the nephelo-
metric assays, SRM and SPE illustrate that it is challenging to
properly calibrate a platform for a heterogeneous analyte like
sFLC. While the agreement between SPE and SRM shown in
Table S-3 in the Supporting Information suggests that SRM is
less sensitive to such heterogeneities than immunoassays, and
remaining diﬀerences between, for example, cognate peptide
pairs in SRM data show that also the accuracy in SRM could be
improved. The comparison of accuracy and standardization of
the techniques is hampered by the lack of an internationally
accepted sFLC reference material. We believe the SRM
approach has the potential to become a reference method
that can harmonize data from diﬀerent analytical platforms.
However, we also believe that the SRM workﬂow needs more
reﬁnement and maturity before this goal can be achieved.
Outlook. The data shown in this paper illustrates the
potential of an SRM method in the quantiﬁcation of intact
immunoglobulins and sFLC. The method delivers data
comparable to the current standard nephelometric assays but
without some of the drawbacks encountered in aﬃnity-based
methods. Moreover, as clinical laboratories introduce mass
spectrometry instrumentation, it is increasingly attractive to
transfer assays to this equipment. Our measurements illustrate
that the assay is readily portable to instruments from diﬀerent
vendors.
For future work on this SRM assay for sFLC, we would
recommend modiﬁcations that could improve to several aspects
of the assay. Some peptides were rejected from the set used for
quantiﬁcation and could be omitted from the set of reference
peptides, while standards should be added for IgD and IgE. The
peptides VPTGGVEEGLLER, TPECPSHTQPLGVYLLTPAV-
QDLWLR, and AVHEAASPSQTVQR performed well for this
purpose.
Improvements may be achieved in cost and eﬃciency as well.
Conservative conditions were chosen for LC runtime (1 h/
sample) and trypsin digestion (overnight). However, other
studies as well as pilot data from our lab show that a shorter
digestion of 3 h and reduction of the gradient length to 10 min
can produce acceptable results.
In nephelometric assays, the performance relies on antibody
reagents which may suﬀer from batch-to-batch variations,
especially in the case of polyclonal antibodies. Moreover, assay
antibodies may fail to interact as expected with their
heterogeneous analytes or suﬀer from antigen excess problems
when analyte concentrations are high. As the nephelometric
assays yield a single numeric result, there is often no hint from
the data that the measurement may have been anomalous.
The only aﬃnity interaction remaining in the SRM workﬂow
is the depletion of intact immunoglobulins. This step could be
implemented with monoclonal antibodies, which would make
the procedure more resistant against batch-to-batch variations.
While problems in the depletion are visible in the data, a more
complete depletion of all isotypes would result in a better
accuracy of the results, especially in the case of gammopathies
belonging to such isotypes. Other or additional depletion
reagents may be helpful, but alternative approaches to the
depletion of intact immunoglobulins may also be of interest,
such as diaﬁltration of high molecular weight proteins from a
serum sample or immunoprecipitation of sFLC with immobi-
lized aﬃnity reagents followed by SRM analysis of the bound
material. The eﬃcacy and cost-eﬀectiveness of such alternative
sample preparations remains to be shown, while aﬃnity
methods should also not inherit some of the drawbacks
associated with the nephelometric immunoassays. Thus, while
speciﬁc pitfalls remain in SRM assays, such as problems in
sample preparation or polymorphisms, most issues can be
revealed from the integrated data set.
■ CONCLUSION
The work in this paper shows that SRM is a promising method
for the quantitation of immunoglobulins and sFLC. While
additional optimizations would be needed, the data already
show that sFLC measurements with SRM were comparable to
those obtained by nephelometry. SRM has a wide measurement
range and is not prone to analytical issues such as nonlinearity
and antigen excess. Before the method can be implemented in a
clinical context, additional validations on multiple instruments
and sites are required. If such studies provide satisfactory
results, we believe that our approach can be developed to either
a reference method for the characterization of reference
materials and challenging samples or a substitute for
nephelometric tests for immunoglobulins and sFLC.
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